Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Futibatinib

FDA-approved product (tablet, oral), marketed as Lytgobi.

Registered studies
25
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Futibatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cholangiocarcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Futibatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Futibatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

    NCT04601857 · start 2021-01-07

    Registered record
    Registry ID
    NCT04601857
    Conditions
    Advanced and Metastatic Urothelial Cancer
    Interventions
    Futibatinib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-01-07
    Completion
    2025-09-16
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced and Metastatic Urothelial Cancer
    InterventionFutibatinib; Pembrolizumab
    PhasePhase 2
    Registry statusTerminated

  • Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

    NCT04093362 · start 2021-01-06

    Registered record
    Registry ID
    NCT04093362
    Conditions
    Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
    Interventions
    Futibatinib; Cisplatin; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-01-06
    Completion
    2024-04-22
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
    InterventionFutibatinib; Cisplatin; Gemcitabine
    PhasePhase 3
    Registry statusTerminated

  • Futibatinib in Patients With Specific FGFR Aberrations

    NCT04189445 · start 2020-08-05

    Registered record
    Registry ID
    NCT04189445
    Conditions
    Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
    Interventions
    Futibatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-08-05
    Completion
    2024-11-11
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
    InterventionFutibatinib
    PhasePhase 2
    Registry statusTerminated

  • A Study of TAS-120 in Patients With Metastatic Breast Cancer

    NCT04024436 · start 2020-01-28

    Registered record
    Registry ID
    NCT04024436
    Conditions
    Metastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification
    Interventions
    Futibatinib; Futibatinib plus Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-01-28
    Completion
    2023-09-06
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; FGFR 1 High Amplification; FGFR2 Amplification
    InterventionFutibatinib; Futibatinib plus Fulvestrant
    PhasePhase 2
    Registry statusTerminated

  • Molecular Profiling of Advanced Soft-tissue Sarcomas

    NCT03784014 · start 2019-10-19

    Registered record
    Registry ID
    NCT03784014
    Conditions
    Soft Tissue Sarcoma
    Interventions
    Nilotinib; Ceritinib; Capmatinib; Lapatinib; Trametinib; Trametinib and Dabrafenib; Olaparib and Durvalumab; Palbociclib; Glasdegib; TAS-120; Next Generation sequencing exome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-19
    Completion
    2026-01-20
    Enrolment
    603

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoft Tissue Sarcoma
    InterventionNilotinib; Ceritinib; Capmatinib; Lapatinib +7 more
    PhasePhase 3
    Registry statusCompleted

  • A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

    NCT03767075 · start 2018-12-10

    Registered record
    Registry ID
    NCT03767075
    Conditions
    Advanced Solid Tumor
    Interventions
    Atezolizumab; Futibatinib; Amivantamab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2018-12-10
    Completion
    2026-11
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionAtezolizumab; Futibatinib; Amivantamab
    PhasePhase 2
    Registry statusRecruiting

  • European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

    NCT02813135 · start 2016-08-03

    Registered record
    Registry ID
    NCT02813135
    Conditions
    Pediatric Cancer
    Interventions
    Ribociclib; Topotecan; Temozolomide; Everolimus; Adavosertib; Carboplatin; Olaparib; Irinotecan; Vistusertib; Nivolumab; Cyclophosphamide; Selumetinib; Enasidenib; Lirilumab; Fadraciclib; Cytarabine; Dexamethasone; Ceralasertib; Futibatinib; Capmatinib; Avelumab; Peposertib; Capivasertib; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2016-08-03
    Completion
    2031-02
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Cancer
    InterventionRibociclib; Topotecan; Temozolomide; Everolimus +20 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    NCT02693535 · start 2016-03-14

    Registered record
    Registry ID
    NCT02693535
    Conditions
    Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
    Interventions
    Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Olaparib; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and Talazoparib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib; Dabrafenib plus Trametinib; Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2016-03-14
    Completion
    2028-12-31
    Enrolment
    4,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
    InterventionSunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib +9 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of TAS-120 in Patients With Advanced Solid Tumors

    NCT02052778 · start 2014-07-21

    Registered record
    Registry ID
    NCT02052778
    Conditions
    Cholangiocarcinoma; Urothelial Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors; Primary CNS Tumors; Breast Cancer; Gastric Cancer
    Interventions
    Futibatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-07-21
    Completion
    2024-10-22
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma; Urothelial Cancer; Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors; Primary CNS Tumors +2 more
    InterventionFutibatinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

    NCT04507503

    Registered record
    Registry ID
    NCT04507503
    Conditions
    Advanced Cholangiocarcinoma
    Interventions
    TAS-120
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cholangiocarcinoma
    InterventionTAS-120
    PhaseNot recorded
    Registry statusApproved for marketing